Meningococcal Infections
48
3
3
41
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
27 trials with published results (56%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
2.1%
1 terminated out of 48 trials
97.6%
+11.1% vs benchmark
44%
21 trials in Phase 3/4
66%
27 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (48)
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Azithromycin for Meningococcal Carriage
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis
Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease
The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults
Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea
Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
Investigating Meningococcal Vaccines in Adults
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV